The 2 analysts offering 12-month price forecasts for Avenue Therapeutics Inc have a median target of 9.00, with a high estimate of 12.00 and a low estimate of 6.00. The median estimate represents a +397.24% increase from the last price of 1.81.
The current consensus among 2 polled investment analysts is to Buy stock in Avenue Therapeutics Inc. This rating has held steady since June, when it was upgraded from a Hold rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.06
Reporting Date Aug 19
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.